Share Twitter LinkedIn Facebook Email Keyan Salari, MD @KeyanSalari of Massachusetts General Hospital @MGHUrology discusses 5-alpha reductase inhibitors and risk of overall and fatal bladder cancer. Advertisement
FDA Approves INLEXZO™ / Gemcitabine Intravesical: A Breakthrough for Bladder Cancer Treatment Bladder 4 Mins Read
FDA Approves New Bladder Cancer Therapy: A Look at Anktiva Nogapendekin Alfa Inbakicept-pmln Bladder 4 Mins Read